- Home
- AUST vs LSTA Comparison
AUST vs LSTA Comparison
Compare AUST & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- LSTA
- Stock Information
- Founded
- AUST 2020
- LSTA 1980
- Country
- AUST Canada
- LSTA United States
- Employees
- AUST N/A
- LSTA N/A
- Industry
- AUST
- LSTA Misc Health and Biotechnology Services
- Sector
- AUST
- LSTA Health Care
- Exchange
- AUST Nasdaq
- LSTA Nasdaq
- Market Cap
- AUST 21.1M
- LSTA 22.3M
- IPO Year
- AUST 2022
- LSTA N/A
- Fundamental
- Price
- AUST $1.73
- LSTA $2.19
- Analyst Decision
- AUST
- LSTA Strong Buy
- Analyst Count
- AUST 0
- LSTA 2
- Target Price
- AUST N/A
- LSTA $23.50
- AVG Volume (30 Days)
- AUST 129.7K
- LSTA 23.3K
- Earning Date
- AUST 11-05-2025
- LSTA 11-11-2025
- Dividend Yield
- AUST N/A
- LSTA N/A
- EPS Growth
- AUST N/A
- LSTA N/A
- EPS
- AUST N/A
- LSTA N/A
- Revenue
- AUST N/A
- LSTA $1,070,000.00
- Revenue This Year
- AUST N/A
- LSTA N/A
- Revenue Next Year
- AUST N/A
- LSTA N/A
- P/E Ratio
- AUST N/A
- LSTA N/A
- Revenue Growth
- AUST N/A
- LSTA N/A
- 52 Week Low
- AUST $0.87
- LSTA $1.87
- 52 Week High
- AUST $3.19
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- AUST 61.44
- LSTA 40.05
- Support Level
- AUST $1.78
- LSTA $2.11
- Resistance Level
- AUST $1.95
- LSTA $2.33
- Average True Range (ATR)
- AUST 0.13
- LSTA 0.16
- MACD
- AUST 0.01
- LSTA -0.01
- Stochastic Oscillator
- AUST 65.18
- LSTA 22.22
About AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.